Announced Fri, 7 Aug · 15:53 IST
Q1 FY27 results: Revenue up 22%, PAT up 30% YoY
Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionExceptional ItemAuditor Mid Year ChangeResults View source PDFExplain this filing
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+3.2%1-day move
₹2050.00
prior close
₹2058.80
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.5+0.5+0.8+0.6+3.2+3.8+3.2+3.8+3.3+3.6————
Up moveDown movePending
AI summary
Q1FY27: Revenue from operations rose 21.9% YoY to Rs 422.43 Cr, driven by strong brand building. PAT grew 30.1% YoY to Rs 60.1 Cr. EBITDA margin expanded 190 bps to 22.0%, PAT margin up 90 bps to 14.2%. EPS stood at Rs 9.83 vs Rs 7.59 YoY. Company inaugurated EU-GMP female hormone plant on 30 June 2026 and is integrating acquired brand Wokadine.
Likely market impact
Strong start to FY27 with double-digit revenue and profit growth, margin expansion, and new plant commissioning signals healthy operational momentum.